FEB 27, 2019 3:00 PM PST

BASKET Trials: Biomarker Driven Drug Development

Presented at: Drug Discovery 2019
Speaker
  • Professor of Medicine (Oncology) and of Radiology (Molecular Imaging Program at Stanford), Director Phase I Clinical Research, Director, Translational Oncology Program, Stanford University
    Biography
      Dr. Shivaani Kummar is a medical oncologist who specializes in early phase clinical drug development. She is Professor of Medicine and Director of the Phase I Clinical Research, Medical Oncology, and Translational Oncology Programs at Stanford University. She trained in Internal Medicine at Emory University in Atlanta, Georgia, and then pursued her fellowship training at the National Institutes of Health in Medical Oncology and Hematology. She then became Assistant Professor of Medicine at Yale Cancer Center, Yale University School of Medicine, where she developed in an interest in developmental therapeutics. She moved back to the National Cancer Institute (NCI), NIH, to build a clinical research program in novel cancer therapeutics and in 2011 became Head of Early Clinical Trials Development in the Office of the Director, Division of Cancer Treatment and Diagnosis, NCI. She subsequently moved to Stanford University in 2015 to create their early phase program in medical oncology. Her research interests focus on developing novel therapies for cancer, conducting pharmacokinetic and pharmacodynamic driven first-in-human trials. The clinical studies integrate genomics, imaging, and laboratory correlates into early phase trials. She serves on multiple national and international committees, and has widely published in high impact peer reviewed journals. She also serves as the Associate Division Chief for Medical Oncology.

    Abstract

    Dramatic responses observed with targeted agents in the ‘right’ genomic context have fueled large scale sequencing efforts to identify ‘effective’ treatments for a given patient. In order to expeditiously evaluate a targeted agent against a potential ‘driver’ genetic aberration, so-called Basket trials are conducted. Basket trials enroll patients with multiple tumor types that carry a common genetic aberration and evaluate a single targeted treatment regimen. I will discuss the rationale, design, and challenges in conducting Basket trials.

    Learning Objectives:

    1. Learn about when to consider conducting a Basket trial and how to design it
    2. Learn about the promises and challenges of identifying patients based on genomic aberrations
     


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    FEB 27, 2019 3:00 PM PST

    BASKET Trials: Biomarker Driven Drug Development

    Presented at: Drug Discovery 2019

    Specialty

    Cancer

    Clinical Diagnostics

    Cell Culture

    Immunity

    Biotechnology

    Immunotherapy

    Antibodies

    Virology

    Research

    Immunology

    Life Sciences

    Dna Sequencing

    Diagnostics

    Cell

    Big Data

    Geography

    North America40%

    Europe40%

    Asia20%

    Registration Source

    Website Visitors100%

    Job Title

    Student50%

    Medical Doctor/Specialist25%

    Medical Laboratory Technician25%

    Organization

    Academic Institution60%

    Manufacturer - Other20%

    Clinical Laboratory20%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more